Carolina L Haass-Koffler1,2,3, Kimberly Goodyear2,3, William H Zywiak1, Lorenzo Leggio2,3, George A Kenna1, Robert M Swift1,4. 1. Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, 121 South Main Street, Providence, RI 02912, USA. 2. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, 121 South Main Street, Providence, RI 02912, USA. 3. Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, 10 Center Drive (10CRC/15330), Bethesda, MD 20892-1108, USA. 4. Veterans Affairs Medical Center, 830 Chalkstone Ave, Providence, RI 02908, USA.
Abstract
AIMS: The goal of this study was to evaluate the efficacy of topiramate up to 200 mg/day and of aripiprazole up to 15 mg/day, alone and combined, in reducing alcohol-related outcomes in a human laboratory study. METHOD: This was a 5 week, between-subject, double-blind, placebo-controlled human laboratory study with topiramate [0 mg/day (placebo), 100 mg/day, 200 mg/day] and aripiprazole [0 mg/day (placebo), 7.5 mg/day, 15 mg/day] in 90 non-treatment seeking, heavy drinking, alcohol-dependent individuals. Main outcomes were the efficacy of 200 mg/day topiramate and 15 mg/day aripiprazole, alone and combined, in reducing drinks consumed during an alcohol self-administration procedure (human laboratory phase) and while receiving the study medications prior to the laboratory session (naturalistic drinking phase). Other outcomes in the laboratory phase included alcohol craving, and alcohol biphasic effects. RESULTS: In the human laboratory phase, topiramate 200 mg/day reduced alcohol craving [**P < 0.01] and amplified alcohol-induced stimulation [*P < 0.05], but did not reduce the number of drinks consumed. Topiramate 200 mg/day was also effective in reducing drinking days [*P < 0.05], and alcohol craving [*P < 0.05], in the naturalistic drinking phase. No significant findings were found for aripiprazole for any of the outcomes analyzed. CONCLUSION: Participants receiving 200 mg/day topiramate reported reduced alcohol drinking and craving, and increased alcohol-related stimulation. These findings provide further support for the role of topiramate as a pharmacological treatment for AUD. CLINICALTRIAL.GOV IDENTIFIER: NCT00884884. SHORT SUMMARY: This study tested topiramate and aripiprazole alone and in combination. The results replicate past findings and suggest that topiramate may be an effective treatment for alcohol use disorder. The present results suggest that the combination of topiramate and aripiprazole do not warrant further evaluation.
AIMS: The goal of this study was to evaluate the efficacy of topiramate up to 200 mg/day and of aripiprazole up to 15 mg/day, alone and combined, in reducing alcohol-related outcomes in a human laboratory study. METHOD: This was a 5 week, between-subject, double-blind, placebo-controlled human laboratory study with topiramate [0 mg/day (placebo), 100 mg/day, 200 mg/day] and aripiprazole [0 mg/day (placebo), 7.5 mg/day, 15 mg/day] in 90 non-treatment seeking, heavy drinking, alcohol-dependent individuals. Main outcomes were the efficacy of 200 mg/day topiramate and 15 mg/day aripiprazole, alone and combined, in reducing drinks consumed during an alcohol self-administration procedure (human laboratory phase) and while receiving the study medications prior to the laboratory session (naturalistic drinking phase). Other outcomes in the laboratory phase included alcohol craving, and alcohol biphasic effects. RESULTS: In the human laboratory phase, topiramate 200 mg/day reduced alcohol craving [**P < 0.01] and amplified alcohol-induced stimulation [*P < 0.05], but did not reduce the number of drinks consumed. Topiramate 200 mg/day was also effective in reducing drinking days [*P < 0.05], and alcohol craving [*P < 0.05], in the naturalistic drinking phase. No significant findings were found for aripiprazole for any of the outcomes analyzed. CONCLUSION: Participants receiving 200 mg/day topiramate reported reduced alcohol drinking and craving, and increased alcohol-related stimulation. These findings provide further support for the role of topiramate as a pharmacological treatment for AUD. CLINICALTRIAL.GOV IDENTIFIER: NCT00884884. SHORT SUMMARY: This study tested topiramate and aripiprazole alone and in combination. The results replicate past findings and suggest that topiramate may be an effective treatment for alcohol use disorder. The present results suggest that the combination of topiramate and aripiprazole do not warrant further evaluation.
Authors: Robert Miranda; Hayley Treloar; Alexander Blanchard; Alicia Justus; Peter M Monti; Thomas Chun; Robert Swift; Jennifer W Tidey; Chad J Gwaltney Journal: Addict Biol Date: 2016-01-11 Impact factor: 4.280
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: George A Kenna; William H Zywiak; Robert M Swift; John E McGeary; James S Clifford; Jessica R Shoaff; Cynthia Vuittonet; Samuel Fricchione; Michael Brickley; Kayla Beaucage; Carolina L Haass-Koffler; Lorenzo Leggio Journal: Alcohol Clin Exp Res Date: 2014-04-28 Impact factor: 3.455
Authors: Henry R Kranzler; Jonathan Covault; Richard Feinn; Stephen Armeli; Howard Tennen; Albert J Arias; Joel Gelernter; Timothy Pond; Cheryl Oncken; Kyle M Kampman Journal: Am J Psychiatry Date: 2014-04 Impact factor: 18.112
Authors: Carolina L Haass-Koffler; Roberta Perciballi; Molly Magill; Antonella Loche; Roberto Cacciaglia; Lorenzo Leggio; Robert M Swift Journal: Psychopharmacology (Berl) Date: 2021-11-03 Impact factor: 4.530
Authors: Carolina L Haass-Koffler; Kimberly Goodyear; William H Zywiak; Lorenzo Leggio; George A Kenna; Robert M Swift Journal: Alcohol Alcohol Date: 2018-07-01 Impact factor: 2.826
Authors: Kimberly Goodyear; Talia R Vasaturo-Kolodner; George A Kenna; Robert M Swift; Lorenzo Leggio; Carolina L Haass-Koffler Journal: Am J Drug Alcohol Abuse Date: 2021-09-28 Impact factor: 3.829
Authors: Nestor Szerman; Ignacio Basurte-Villamor; Pablo Vega; Jose Martinez-Raga; Carlos Parro-Torres; Julia Cambra Almerge; Lara Grau-López; Mario De Matteis; Francisco Arias Journal: Drugs Real World Outcomes Date: 2020-03
Authors: Carolina L Haass-Koffler; Daria Piacentino; Xiaobai Li; Victoria M Long; Mary R Lee; Robert M Swift; George A Kenna; Lorenzo Leggio Journal: Alcohol Clin Exp Res Date: 2020-09-30 Impact factor: 3.928